Beth Evans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Beth Evans has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Thibaut Jombart
Imperial College London
5 shared publications Laurent Kaiser
Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland
4 shared publicationsOlivia Keiser
Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland
4 shared publicationsThibaut Jombart
MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, UK
3 shared publications- Laurent Kaiser
Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals and University of Geneva
2 shared publications - Olivia Keiser
Institute of Global Health, University of Geneva, Geneva, Switzerland
2 shared publications
Latest Publications
- Open Access
- 10 June 2025
- Published by Elsevier in Public Health
- Vol. 246, 105813
Pre-pandemic national immunisation programme strength and health workforce capacity improved routine immunisation resilience during the COVID-19 pandemic
- 10 June 2025
- Published by Elsevier in Public Health
- Vol. 246, 105813
Open AccessPre-pandemic national immunisation programme strength and health workforce capacity improved routine immunisation resilience during the COVID-19 pandemic
- Open Access
Routine Immunisation Coverage Shows Signs of Recovery at Global Level Postpandemic, but Important Declines Persist in About 20% of Countries
Background/Objectives: Routine immunisation (RI) coverage declines during the COVID-19 pandemic, from 2020 to 2022, are well-reported. With the declared end to the Public Health Emergency of International Concern in May 2023, and the cessation of most nonpharmaceutical interventions that were introduced to prevent or minimise COVID-19 spread, we (I) assess whether routine immunisation coverage has rebounded to the level of prepandemic trends and (II) seek to identify factors that help predict whether country performance has exceeded, maintained, or declined compared with expectations (based on time-series forecasting). Methods: We quantified global and country-level routine immunisation diphtheria–tetanus–pertussis (DTP) coverage trends postpandemic (2023) compared with prepandemic trends using time-series forecasting across 190 countries. We used discriminant analysis of principal components and random forests to identify relevant predictors of country-level coverage performance, including twenty-eight indicators of health system strength, health workforce, country income, pandemic containment, economic and health policies, and demographic aspects. Results: We show that mean global DTP third-dose coverage levels remained on average 2.7% [95% confidence intervals: 1.1–4.3%] lower than expected in 2023. However, once accounting for temporal demographic changes, we find that this translated to the total number of immunised children almost reverting to expected levels because of decreasing fertility reducing global-level immunisation target populations. At the country level, notable disruption remained in over thirty countries (16.8% of countries below expectations, 81.6% within expected ranges, and 1.6% above expectations). Neither predictive method performed well at identifying factors associated with coverage disruptions. Conclusions: Despite the end of COVID-19 pandemic measures, RI remains below expectations in about 20% of countries. No clear drivers of this continued disruption were identified. Further research is required to inform recovery efforts and prevent future epidemic and pandemic disruptions to routine health services.
Open AccessRoutine Immunisation Coverage Shows Signs of Recovery at Global Level Postpandemic, but Important Declines Persist in About 20% of Countries
Background/Objectives: Routine immunisation (RI) coverage declines during the COVID-19 pandemic, from 2020 to 2022, are well-reported. With the declared end to the Public Health Emergency of International Concern in May 2023, and the cessation of most nonpharmaceutical interventions that were introduced to prevent or minimise COVID-19 spread, we (I) assess whether routine immunisation coverage has rebounded to the level of prepandemic trends and (II) seek to identify factors that help predict whether country performance has exceeded, maintained, or declined compared with expectations (based on time-series forecasting). Methods: We quantified global and country-level routine immunisation diphtheria–tetanus–pertussis (DTP) coverage trends postpandemic (2023) compared with prepandemic trends using time-series forecasting across 190 countries. We used discriminant analysis of principal components and random forests to identify relevant predictors of country-level coverage performance, including twenty-eight indicators of health system strength, health workforce, country income, pandemic containment, economic and health policies, and demographic aspects. Results: We show that mean global DTP third-dose coverage levels remained on average 2.7% [95% confidence intervals: 1.1–4.3%] lower than expected in 2023. However, once accounting for temporal demographic changes, we find that this translated to the total number of immunised children almost reverting to expected levels because of decreasing fertility reducing global-level immunisation target populations. At the country level, notable disruption remained in over thirty countries (16.8% of countries below expectations, 81.6% within expected ranges, and 1.6% above expectations). Neither predictive method performed well at identifying factors associated with coverage disruptions. Conclusions: Despite the end of COVID-19 pandemic measures, RI remains below expectations in about 20% of countries. No clear drivers of this continued disruption were identified. Further research is required to inform recovery efforts and prevent future epidemic and pandemic disruptions to routine health services.
- Open Access
- 27 February 2025
- Published by MDPI AG in Preprints.org
Routine Immunisation Coverage Shows Signs of Recovery at Global-Level Post Pandemic, But Important and Declines Persist in 20% of Countries
Background/Objectives: Routine immunisation (RI) coverage declines during the COVID-19 pandemic, from 2020 to 2022, are well-reported. With the declared end to the Public Health Emergency of International Concern in May 2023, and the end of most non-pharmaceutical interventions that were introduced to prevent or minimise COVID-19 spread, we (I) assess whether routine immunisation coverage has rebounded to pre-pandemic trends, and (II) seek to identify factors that help predict whether country performance has exceeded, maintained, or declined compared to expectations (based on time-series forecasting). Methods: We quantify global and country-level routine immunisation diphtheria-tetanus-pertussis (DTP) coverage trends post-pandemic (2023) compared to pre-pandemic trends using time-series forecasting across 190 countries. We used Discriminant Analysis of Principal Components and Random Forests to identify relevant predictors of country-level coverage performance, including 28 indicators of health system strength, health workforce, country income, pandemic containment, economic, and health policies, and demographic aspects. Results: We show that mean global DTP third-dose coverage levels remained on average 2.7% [95% confidence intervals: 1.1% - 4.3%] lower than expected in 2023. However, once accounting for temporal demographic changes, we find that this translates to the total number of immunised children almost reverting to expected levels, owing to decreasing fertility reducing global-level immunisation target populations. At a country-level, notable disruption remaining in over 30 countries (17.6% of countries below expectations, 81.6 within expected ranges, and 1.7% above expectations). Neither predictive method performed well at identifying factors associated with coverage disruptions. Conclusions: Despite the end of COVID-19 pandemic measures, RI remains below expectations in 20% of countries. No clear drivers of this continued disruption were identified. Further research is required to inform recovery efforts and prevent future epidemic and pandemic disruptions to routine health services.
- 27 February 2025
- Published by MDPI AG in Preprints.org
Open AccessRoutine Immunisation Coverage Shows Signs of Recovery at Global-Level Post Pandemic, But Important and Declines Persist in 20% of Countries
Background/Objectives: Routine immunisation (RI) coverage declines during the COVID-19 pandemic, from 2020 to 2022, are well-reported. With the declared end to the Public Health Emergency of International Concern in May 2023, and the end of most non-pharmaceutical interventions that were introduced to prevent or minimise COVID-19 spread, we (I) assess whether routine immunisation coverage has rebounded to pre-pandemic trends, and (II) seek to identify factors that help predict whether country performance has exceeded, maintained, or declined compared to expectations (based on time-series forecasting). Methods: We quantify global and country-level routine immunisation diphtheria-tetanus-pertussis (DTP) coverage trends post-pandemic (2023) compared to pre-pandemic trends using time-series forecasting across 190 countries. We used Discriminant Analysis of Principal Components and Random Forests to identify relevant predictors of country-level coverage performance, including 28 indicators of health system strength, health workforce, country income, pandemic containment, economic, and health policies, and demographic aspects. Results: We show that mean global DTP third-dose coverage levels remained on average 2.7% [95% confidence intervals: 1.1% - 4.3%] lower than expected in 2023. However, once accounting for temporal demographic changes, we find that this translates to the total number of immunised children almost reverting to expected levels, owing to decreasing fertility reducing global-level immunisation target populations. At a country-level, notable disruption remaining in over 30 countries (17.6% of countries below expectations, 81.6 within expected ranges, and 1.7% above expectations). Neither predictive method performed well at identifying factors associated with coverage disruptions. Conclusions: Despite the end of COVID-19 pandemic measures, RI remains below expectations in 20% of countries. No clear drivers of this continued disruption were identified. Further research is required to inform recovery efforts and prevent future epidemic and pandemic disruptions to routine health services.
- Open Access
Pre-pandemic national immunisation programme strength and health workforce capacity improved routine immunisation resilience during the COVID-19 pandemic
Background: The adverse impact of the COVID-19 pandemic on Routine Immunisation (RI) coverage has been well-documented: most countries experienced backsliding or stagnation in coverage. Qualitative surveys indicated potential causes of such declines, including reduced health care seeking behaviour, lockdowns, and overwhelmed health systems. Methods: We investigate determinants of RI resilience during COVID-19 at a national level for 119 countries from 2020 to 2022, using publicly available data on pre-pandemic immunisation programme performance, health workforce capacity, health systems strength, health financing, global health security preparedness, COVID-19 burden, COVID-19 containment, economic, and health policy responses, population mobility changes, and country wealth. We employ a mixed methods approach: stepwise linear regression based on a causal inference framework, and Random Forest regression to identify potential nonlinear interactions and collinear effects. Results: We provide evidence that stronger pre-pandemic immunisation programmes and more health workers, once above minimum thresholds (about 83% Diphtheria-Tetanus-Pertussis third-dose coverage and 60 health workers per 10,000 population), are associated with improved RI resilience. Random Forest analysis suggests health financing and health system strength impact RI resilience. COVID-19 vaccinations and pandemic policies were not associated with RI coverage changes, implying – reassuring – these acute responses did not interrupt routine services. In addition to these findings, a large fraction of variation in pandemic RI resilience remains unexplained, highlighting the need for further research on RI performance determinants. Conclusion: Our findings underscore the role of robust immunisation programmes and sufficiently sized health workforces in mitigating RI disruption during global health crises once above minimum thresholds. Reassuringly, we do not find evidence that COVID-19 vaccination campaigns nor pandemic containment policies impacted RI performance – counter to qualitative survey indications. We encourage continued efforts to identify RI disruption determinants to inform the evidence base for public health practitioners globally.
Open AccessPre-pandemic national immunisation programme strength and health workforce capacity improved routine immunisation resilience during the COVID-19 pandemic
Background: The adverse impact of the COVID-19 pandemic on Routine Immunisation (RI) coverage has been well-documented: most countries experienced backsliding or stagnation in coverage. Qualitative surveys indicated potential causes of such declines, including reduced health care seeking behaviour, lockdowns, and overwhelmed health systems. Methods: We investigate determinants of RI resilience during COVID-19 at a national level for 119 countries from 2020 to 2022, using publicly available data on pre-pandemic immunisation programme performance, health workforce capacity, health systems strength, health financing, global health security preparedness, COVID-19 burden, COVID-19 containment, economic, and health policy responses, population mobility changes, and country wealth. We employ a mixed methods approach: stepwise linear regression based on a causal inference framework, and Random Forest regression to identify potential nonlinear interactions and collinear effects. Results: We provide evidence that stronger pre-pandemic immunisation programmes and more health workers, once above minimum thresholds (about 83% Diphtheria-Tetanus-Pertussis third-dose coverage and 60 health workers per 10,000 population), are associated with improved RI resilience. Random Forest analysis suggests health financing and health system strength impact RI resilience. COVID-19 vaccinations and pandemic policies were not associated with RI coverage changes, implying – reassuring – these acute responses did not interrupt routine services. In addition to these findings, a large fraction of variation in pandemic RI resilience remains unexplained, highlighting the need for further research on RI performance determinants. Conclusion: Our findings underscore the role of robust immunisation programmes and sufficiently sized health workforces in mitigating RI disruption during global health crises once above minimum thresholds. Reassuringly, we do not find evidence that COVID-19 vaccination campaigns nor pandemic containment policies impacted RI performance – counter to qualitative survey indications. We encourage continued efforts to identify RI disruption determinants to inform the evidence base for public health practitioners globally.
- Open Access
- 6 September 2023
- Published by Elsevier in Vaccine: X
- Vol. 15, 100383
Analysis of global routine immunisation coverage shows disruption and stagnation during the first two-years of the COVID-19 pandemic with tentative recovery in 2022
- 6 September 2023
- Published by Elsevier in Vaccine: X
- Vol. 15, 100383
Open AccessAnalysis of global routine immunisation coverage shows disruption and stagnation during the first two-years of the COVID-19 pandemic with tentative recovery in 2022
- Open Access
Time series analysis of routine immunisation coverage during the COVID-19 pandemic in 2021 shows continued global decline and increases in Zero Dose children
Whilst it is now widely recognised that routine immunisation (RI) was disrupted by the COVID-19 pandemic in 2020 compared to previous immunisation performance, the extent of continued interruptions in 2021 and/or rebounds to previous trends remains unclear, with sporadic surveys reporting signs of immunisation system recovery at the end of 2020. We modelled country-specific RI trends using validated estimates of national coverage from the World Health Organisation and United Nation Children’s Fund for over 160 countries, to project expected diphtheria, tetanus, and pertussis-containing vaccine first-dose (DTP1), third-dose (DTP3) and measles-containing vaccine first-dose (MCV1) coverage for 2021 based on pre-pandemic trends (from 2000-2019). We estimated a 3·6% (95%CI: [2·6%; 4·6%]) decline in global DTP3 coverage in 2021 compared to 2000-2019 trends, from an expected 90·1% to a reported 86·5% across 164 reporting countries, and similar results for DTP1 (2·8% decline; 95%CI: [2·0%; 3·6%]), and for MCV1 (3·8% decline; 95%CI: [4·8%; 2·7%]). 86·5% global coverage in 2021 represents a further decrease from that reported in 2020 and 2019, and translates to a 16-year setback in RI coverage, i.e., 2005 levels. Hypothesised and early signals of rebounds to pre-pandemic coverage were not seen in most countries. The Americas, Africa, and Asia were the most impacted regions, with low- and middle-income countries the most affected income groups. The number of Zero Dose children also continued to increase in 2021. DTP1 coverage declined worldwide from an expected 93·7% to a reported 90·9% (2·8% decline; 95%CI: [2·0%; 3·6%]) which translates into an additional 3.4 million Zero Dose children on top of an expected 11.0 million (30.9% increase) at the global level. We hope this work will provide an objective baseline to inform future interventions and prioritisation aiming to facilitate rebounds in coverage to previous levels and catch-up of growing populations of under- and un-immunised children.
Open AccessTime series analysis of routine immunisation coverage during the COVID-19 pandemic in 2021 shows continued global decline and increases in Zero Dose children
Whilst it is now widely recognised that routine immunisation (RI) was disrupted by the COVID-19 pandemic in 2020 compared to previous immunisation performance, the extent of continued interruptions in 2021 and/or rebounds to previous trends remains unclear, with sporadic surveys reporting signs of immunisation system recovery at the end of 2020. We modelled country-specific RI trends using validated estimates of national coverage from the World Health Organisation and United Nation Children’s Fund for over 160 countries, to project expected diphtheria, tetanus, and pertussis-containing vaccine first-dose (DTP1), third-dose (DTP3) and measles-containing vaccine first-dose (MCV1) coverage for 2021 based on pre-pandemic trends (from 2000-2019). We estimated a 3·6% (95%CI: [2·6%; 4·6%]) decline in global DTP3 coverage in 2021 compared to 2000-2019 trends, from an expected 90·1% to a reported 86·5% across 164 reporting countries, and similar results for DTP1 (2·8% decline; 95%CI: [2·0%; 3·6%]), and for MCV1 (3·8% decline; 95%CI: [4·8%; 2·7%]). 86·5% global coverage in 2021 represents a further decrease from that reported in 2020 and 2019, and translates to a 16-year setback in RI coverage, i.e., 2005 levels. Hypothesised and early signals of rebounds to pre-pandemic coverage were not seen in most countries. The Americas, Africa, and Asia were the most impacted regions, with low- and middle-income countries the most affected income groups. The number of Zero Dose children also continued to increase in 2021. DTP1 coverage declined worldwide from an expected 93·7% to a reported 90·9% (2·8% decline; 95%CI: [2·0%; 3·6%]) which translates into an additional 3.4 million Zero Dose children on top of an expected 11.0 million (30.9% increase) at the global level. We hope this work will provide an objective baseline to inform future interventions and prioritisation aiming to facilitate rebounds in coverage to previous levels and catch-up of growing populations of under- and un-immunised children.
- Open Access
Worldwide routine immunisation coverage regressed during the first year of the COVID-19 pandemic
- Open Access
Worldwide routine immunisation coverage regressed during the first year of the COVID-19 pandemic
We modelled historical, country-specific routine immunisation trends using publicly available vaccination coverage data for diphtheria, tetanus and pertussis-containing vaccine first-dose (DTP1) and third-dose (DTP3) from 2000 to 2019. We evaluate changes in coverage in 2020 by comparing model predictions to WUENIC-reported coverage. We report a 2.9% (95% CI : [2.2%; 3.6%]) global decline in DTP3 coverage, and important increases in missed immunisations in some countries with middle-income countries, and the Americas, being most affected.
Open AccessWorldwide routine immunisation coverage regressed during the first year of the COVID-19 pandemic
We modelled historical, country-specific routine immunisation trends using publicly available vaccination coverage data for diphtheria, tetanus and pertussis-containing vaccine first-dose (DTP1) and third-dose (DTP3) from 2000 to 2019. We evaluate changes in coverage in 2020 by comparing model predictions to WUENIC-reported coverage. We report a 2.9% (95% CI : [2.2%; 3.6%]) global decline in DTP3 coverage, and important increases in missed immunisations in some countries with middle-income countries, and the Americas, being most affected.
- 30 April 2012
- Published by Royal College of Nursing in Primary Health Care
- Vol. 22 (4) , 26-29
How to improve primary care by using significant event audit
- 30 April 2012
- Published by Royal College of Nursing in Primary Health Care
- Vol. 22 (4) , 26-29
How to improve primary care by using significant event audit